Evogene subsidiary Lavie Bio announces commercial expansion of Yalos treatment

Evogene (EVGN) subsidiary Lavie Bio announced the commercial expansion of Yalos seed-treatment to soybean, following successful field trials performed in 2024 in the US. Yalos, Lavie Bio’s first commercial bio-inoculant product available in the US and Canada, demonstrated yield increase by more than 5% on average, in soybean. Yalos is comprised of two novel microbes that together improve early vigor, biomass, root and shoot development, and nutrient availability. It aims to improve emergence and establishment and increase farm productivity through advanced biological technologies.Currently, Yalos is sold in North America as a seed-treatment for spring and winter wheat, durum and barley, distributed in Canada by Winfield United and in the US directly by Lavie Bio. As of spring 2025, Lavie Bio intends Yalos(R) to be commercially available for soybean as well. This expansion more than doubles the potential market for Yalos(R) compared to markets in which Lavie Bio already operates.